Novo Holdings to acquire Catalent for $11.5 billion; cancer incidence is expected to surge 77% by 2050; Silicon Valley’s county takes a bold step to address the rising loneliness crisis.
Novo Holdings, parent company to Novo Nordisk, is set to acquire Catalent in a significant $11.5 billion deal, signaling a strategic move to expand the production capacity of semaglutide (Wegovy), according to Reuters. Catalent is the main supplier of filling and packaging syringes and injection pens for Novo Nordisk’s weight loss medication. The deal is poised to strengthen Novo Holdings' position in the pharmaceutical industry while addressing the rising global concerns around obesity and related health issues.
The World Health Organization (WHO) has released a concerning report indicating a projected 77% increase in global cancer cases by 2050, according to CNN. The organization has emphasized the urgent need for comprehensive measures to tackle this growing health crisis, advocating for enhanced prevention, early detection, and improved access to treatment. The report underscored the importance of international collaboration and coordinated efforts to implement effective strategies in the battle against cancer, highlighting the pressing need for a unified global response.
San Mateo County in the California Bay Area, which includes part of Silicon Valley, has declared loneliness a public health emergency, acknowledging its profound impact on mental well-being, according to NBC News. This groundbreaking move reflects a growing recognition of the negative health consequences associated with social isolation and underscores the county's commitment to addressing mental health challenges. By designating loneliness as a priority, San Mateo County aims to pioneer innovative solutions and community-based initiatives to foster social connections, setting a precedent for other regions to prioritize mental health in public policy.
Dr Kathy Zackowski Discusses the Importance of Rehabilitation Research and Trials in MS
April 26th 2024Kathy Zackowski, PhD, National MS Society, expresses the inherent value of quality rehabilitation trials for broadening clinical understandings of multiple sclerosis (MS) and bettering patient outcomes.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen